Ophthalmology Guidelines for Use of Aflibercept (Eylea®)

**Wet Age Related Macular Degeneration (ARMD)**

**Indications for Use:**
- Following failure or toxicity of bevacizumab (off-label) or ranibizumab (Lucentis®)

**Dose and Administration:**
- Aflibercept 2 mg (0.05 mL) via intravitreal injection once every 4 weeks for 3 months, followed by 2 mg via intravitreal injection once every 8 weeks for 2 months.
- Aflibercept may be dosed as frequently as 2 mg every 4 weeks after the first 3 months.

**Macular Edema from Retinal Vein Occlusion (RVO)**

**Indications for Use:**
- Following failure or toxicity of bevacizumab (off-label) or ranibizumab (Lucentis®)
- Following failure or inability to perform macular focal laser photocoagulation

**Dose and Administration:**
- Aflibercept 2 mg via intravitreal injection every 4 weeks

**Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)**

**Indications for Use:**
- Following failure or toxicity of bevacizumab (off-label) or ranibizumab (Lucentis®)
- Following failure or inability to perform macular focal laser photocoagulation

**Dose and Administration:**
- Aflibercept 2 mg via intravitreal once every 4 weeks for 5 months, followed by 2 mg intravitreal injection once every 8 weeks for 2 months.
- Aflibercept may be dosed as frequently as 2 mg every 4 weeks after the first 5 months.